Dyne Therapeutics (DYN) Competitors $28.39 -1.92 (-6.33%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DYN vs. DRNA, ARWR, PTGX, AMPH, FPRX, RDY, PCVX, SRPT, CTLT, and RVMDShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Dicerna Pharmaceuticals (DRNA), Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), Amphastar Pharmaceuticals (AMPH), Five Prime Therapeutics (FPRX), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector. Dyne Therapeutics vs. Dicerna Pharmaceuticals Arrowhead Pharmaceuticals Protagonist Therapeutics Amphastar Pharmaceuticals Five Prime Therapeutics Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Catalent Revolution Medicines Dyne Therapeutics (NASDAQ:DYN) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership. Does the media favor DYN or DRNA? In the previous week, Dyne Therapeutics had 16 more articles in the media than Dicerna Pharmaceuticals. MarketBeat recorded 16 mentions for Dyne Therapeutics and 0 mentions for Dicerna Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.36 beat Dicerna Pharmaceuticals' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dyne Therapeutics Neutral Dicerna Pharmaceuticals Neutral Is DYN or DRNA more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Dicerna Pharmaceuticals' net margin of -64.53%. Dyne Therapeutics' return on equity of -57.46% beat Dicerna Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -57.46% -51.62% Dicerna Pharmaceuticals -64.53%-103.08%-16.58% Do analysts prefer DYN or DRNA? Dyne Therapeutics presently has a consensus target price of $51.40, suggesting a potential upside of 81.05%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than Dicerna Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Dicerna Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, DYN or DRNA? Dyne Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Do institutionals & insiders have more ownership in DYN or DRNA? 96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 78.9% of Dicerna Pharmaceuticals shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 10.2% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer DYN or DRNA? Dicerna Pharmaceuticals received 425 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 70.73% of users gave Dyne Therapeutics an outperform vote while only 61.10% of users gave Dicerna Pharmaceuticals an outperform vote. CompanyUnderperformOutperformDyne TherapeuticsOutperform Votes2970.73% Underperform Votes1229.27% Dicerna PharmaceuticalsOutperform Votes45461.10% Underperform Votes28938.90% Which has preferable valuation and earnings, DYN or DRNA? Dicerna Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$235.94M-$3.56-7.97Dicerna Pharmaceuticals$164.31M18.17-$112.75M-$1.63-23.45 SummaryDyne Therapeutics beats Dicerna Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.89B$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-7.9710.0598.5017.08Price / SalesN/A266.581,205.7371.31Price / CashN/A53.4940.6936.36Price / Book4.109.306.325.87Net Income-$235.94M$154.14M$119.47M$225.66M7 Day Performance-0.32%-9.49%-5.11%-1.34%1 Month Performance-19.80%-7.23%-3.21%1.00%1 Year Performance190.73%30.70%32.41%25.27% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.4735 of 5 stars$28.39-6.3%$51.40+81.0%+190.7%$2.89BN/A-7.97100Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageDRNADicerna Pharmaceuticals1.0929 of 5 stars$38.22flatN/AN/A$2.99B$164.31M-23.45302ARWRArrowhead Pharmaceuticals3.7112 of 5 stars$21.63+0.6%N/A-28.7%$2.69B$240.74M-4.63400Analyst UpgradeNews CoveragePTGXProtagonist Therapeutics3.0657 of 5 stars$42.67-1.2%N/A+155.0%$2.54B$60M16.04125Analyst RevisionAMPHAmphastar Pharmaceuticals4.88 of 5 stars$45.48-4.7%N/A-20.6%$2.19B$644.40M15.161,761Insider SellingFPRXFive Prime TherapeuticsN/A$38.00flatN/AN/A$1.77B$14.87M-14.1887RDYDr. Reddy's Laboratories1.3454 of 5 stars$14.56-1.4%N/A+6.7%$12.15B$3.35B23.2627,048Analyst DowngradeShort Interest ↑PCVXVaxcyte3.3295 of 5 stars$96.63-2.8%N/A+73.3%$12.04BN/A-21.01160News CoverageHigh Trading VolumeSRPTSarepta Therapeutics4.9455 of 5 stars$112.48-1.6%N/A+26.0%$10.74B$1.24B89.981,314Analyst UpgradeCTLTCatalent2.8783 of 5 stars$59.15-0.2%N/A+48.7%$10.74B$4.42B-26.1716,900Analyst UpgradeInsider SellingNews CoverageRVMDRevolution Medicines3.5596 of 5 stars$58.13-2.0%N/A+159.4%$9.78B$11.58M-16.19443 Related Companies and Tools Related Companies Dicerna Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Protagonist Therapeutics Competitors Amphastar Pharmaceuticals Competitors Five Prime Therapeutics Competitors Dr. Reddy's Laboratories Competitors Vaxcyte Competitors Sarepta Therapeutics Competitors Catalent Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DYN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
